Cargando…
Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients.
Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions othe...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228019/ https://www.ncbi.nlm.nih.gov/pubmed/9303359 |
_version_ | 1782149818936721408 |
---|---|
author | Cariuk, P. Lorite, M. J. Todorov, P. T. Field, W. N. Wigmore, S. J. Tisdale, M. J. |
author_facet | Cariuk, P. Lorite, M. J. Todorov, P. T. Field, W. N. Wigmore, S. J. Tisdale, M. J. |
author_sort | Cariuk, P. |
collection | PubMed |
description | Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice. IMAGES: |
format | Text |
id | pubmed-2228019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-22280192009-09-10 Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Cariuk, P. Lorite, M. J. Todorov, P. T. Field, W. N. Wigmore, S. J. Tisdale, M. J. Br J Cancer Research Article Urine from cancer patients with weight loss showed the presence of an antigen of M(r) 24,000 detected with a monoclonal antibody formed by fusion of splenocytes from mice with cancer cachexia. The antigen was not present in the urine of normal subjects, patients with weight loss from conditions other than cancer or from cancer patients who were weight stable or with low weight loss (1 kg month(-1)). The antigen was present in the urine from subjects with carcinomas of the pancreas, breast, lung and ovary. The antigen was purified from urine using a combination of affinity chromatography with the mouse monoclonal antibody and reversed-phase high-performance liquid chromotography (HPLC). This procedure gave a 200,000-fold purification of the protein over that in the original urine extract and the material isolated was homogeneous, as determined by silver staining of gels. The N-terminal amino acid sequence showed no homology with any of the recognized cytokines. Administration of this material to mice caused a significant (P<0.005) reduction in body weight when compared with a control group receiving material purified in the same way from the urine of a normal subject. Weight loss occurred without a reduction in food and water intake and was prevented by prior administration of the mouse monoclonal antibody. Body composition analysis showed a decrease in both fat and non-fat carcass mass without a change in water content. The effects on body composition were reversed in mice treated with the monoclonal antibody. There was a decrease in protein synthesis and an increase in degradation in skeletal muscle. Protein degradation was associated with an increased prostaglandin E2 (PGE2) release. Both protein degradation and PGE2 release were significantly reduced in mice pretreated with the monoclonal antibody. These results show that the material of M(r) 24,000 present in the urine of cachectic cancer patients is capable of producing a syndrome of cachexia in mice. IMAGES: Nature Publishing Group 1997 /pmc/articles/PMC2228019/ /pubmed/9303359 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Cariuk, P. Lorite, M. J. Todorov, P. T. Field, W. N. Wigmore, S. J. Tisdale, M. J. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
title | Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
title_full | Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
title_fullStr | Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
title_full_unstemmed | Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
title_short | Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
title_sort | induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228019/ https://www.ncbi.nlm.nih.gov/pubmed/9303359 |
work_keys_str_mv | AT cariukp inductionofcachexiainmicebyaproductisolatedfromtheurineofcachecticcancerpatients AT loritemj inductionofcachexiainmicebyaproductisolatedfromtheurineofcachecticcancerpatients AT todorovpt inductionofcachexiainmicebyaproductisolatedfromtheurineofcachecticcancerpatients AT fieldwn inductionofcachexiainmicebyaproductisolatedfromtheurineofcachecticcancerpatients AT wigmoresj inductionofcachexiainmicebyaproductisolatedfromtheurineofcachecticcancerpatients AT tisdalemj inductionofcachexiainmicebyaproductisolatedfromtheurineofcachecticcancerpatients |